Please enable JavaScript to continue using this application.

Compare $CAI vs $KYMR | Chartloom

Compare

$CAI vs $KYMR

Caris Life Sciences Inc · Kymera Therapeutics Inc

CAI

Caris Life Sciences Inc

KYMR

Kymera Therapeutics Inc

Compare $CAI vs $KYMR

Comparing Caris Life Sciences Inc and Kymera Therapeutics Inc

CAICaris Life Sciences Inc

KYMRKymera Therapeutics Inc

CAICaris Life Sciences Inc

Market cap

$8.40B

P/E (TTM)

79.91x

Forward P/E (NTM)

101.64x

Forward P/S (NTM)

7.48x

Rev growth (TTM)

24.4%

YTD performance

10.1%

52W performance

-9.9%

FCF yield

1.5%

KYMRKymera Therapeutics Inc

Market cap

$9.25B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

456.91x

Rev growth (TTM)

134.8%

YTD performance

54.5%

52W performance

99.7%

FCF yield

-2.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CAI

KYMR

Detailed metrics comparison

CAI

Caris Life Sciences Inc

KYMR

Kymera Therapeutics Inc

Market Cap

CAI$8.40B

KYMR$9.25B

Enterprise Value

CAI$8.10B

KYMR$9.12B

Price

CAI$29.70

KYMR$112.40

P/E Ratio

CAI79.91x

KYMRN/A

P/S Ratio

CAI8.48x

KYMR88.06x

EV/Sales

CAI8.18x

KYMR86.90x

EV/EBITDA

CAI45.95x

KYMR0.00x

P/B Ratio

CAI13.52x

KYMR5.92x

P/FCF Ratio

CAI67.73x

KYMRN/A

EV/FCF

CAI65.33x

KYMR-38.34x

PEG Ratio

CAIN/A

KYMRN/A

Forward P/E (NTM)

CAI101.64x

KYMRN/A

Forward P/S (NTM)

CAI7.48x

KYMR456.91x

Revenue (TTM)

CAI$990M

KYMR$105M

Revenue Growth (YoY)

CAI24.4%

KYMR134.8%

Forward Rev Growth

CAI18.2%

KYMR-62.1%

Gross Margin (TTM)

CAI69.7%

KYMR0.0%

Operating Margin (TTM)

CAI12.7%

KYMR0.0%

EBITDA Margin (TTM)

CAI17.6%

KYMR-322.0%

Net Margin (TTM)

CAI10.6%

KYMR-285.3%

FCF Margin (TTM)

CAI12.5%

KYMR-226.6%

Net Income (TTM)

CAI$105M

KYMR$-300M

FCF (TTM)

CAI$124M

KYMR$-238M

EPS (TTM)

CAI$0.37

KYMR-$3.05

ROE (TTM)

CAI18.8%

KYMR-2150.0%

ROA (TTM)

CAI9.3%

KYMR-1946.0%

ROIC (TTM)

CAI11.2%

KYMR-2145.0%

Cash

CAI$691M

KYMR$124M

Debt

CAI$393M

KYMR$2M

Net Cash/Debt

CAI$298M

KYMR$122M

Current Ratio (TTM)

CAI5.53x

KYMR10.34x

Quick Ratio (TTM)

CAI4.78x

KYMR9.97x

Debt/Equity (TTM)

CAI0.66x

KYMR0.00x

Debt/Assets (TTM)

CAI0.0%

KYMR0.0%

Interest Coverage (TTM)

CAIN/A

KYMRN/A

Net Debt/EBITDA (TTM)

CAI0.00x

KYMR0.00x

Beta

CAI0.40

KYMR2.05

52W Performance

CAI-9.9%

KYMR99.7%

YTD Performance

CAI10.1%

KYMR54.5%

% from 52W High

CAI-11.7%

KYMR-13.6%

% from 52W Low

CAI109.3%

KYMR103.4%

Asset Turnover (TTM)

CAI0.88x

KYMR0.07x

FCF Yield (TTM)

CAI1.5%

KYMR-2.6%

Earnings Yield (TTM)

CAI1.3%

KYMR-3.2%

Dividend Yield (TTM)

CAIN/A

KYMRN/A

Rule of 40

CAI37.0

KYMR-91.8

EV/GP/RG

CAI0.86

KYMRN/A

Ticker research

View CAI research View KYMR research

Metric	CAI Caris Life Sciences Inc	KYMR Kymera Therapeutics Inc
Market & Valuation
Market Cap	$8.40B	$9.25B
Enterprise Value	$8.10B	$9.12B
Price	$29.70	$112.40
P/E Ratio	79.91x	N/A
P/S Ratio	8.48x	88.06x
EV/Sales	8.18x	86.90x
EV/EBITDA	45.95x	0.00x
P/B Ratio	13.52x	5.92x
P/FCF Ratio	67.73x	N/A
EV/FCF	65.33x	-38.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	101.64x	N/A
Forward P/S (NTM)	7.48x	456.91x
Revenue & Growth
Revenue (TTM)	$990M	$105M
Revenue Growth (YoY)	24.4%	134.8%
Forward Rev Growth	18.2%	-62.1%
Profitability
Gross Margin (TTM)	69.7%	0.0%
Operating Margin (TTM)	12.7%	0.0%
EBITDA Margin (TTM)	17.6%	-322.0%
Net Margin (TTM)	10.6%	-285.3%
FCF Margin (TTM)	12.5%	-226.6%
Net Income (TTM)	$105M	$-300M
FCF (TTM)	$124M	$-238M
EPS (TTM)	$0.37	-$3.05
ROE (TTM)	18.8%	-2150.0%
ROA (TTM)	9.3%	-1946.0%
ROIC (TTM)	11.2%	-2145.0%
Financial Health
Cash	$691M	$124M
Debt	$393M	$2M
Net Cash/Debt	$298M	$122M
Current Ratio (TTM)	5.53x	10.34x
Quick Ratio (TTM)	4.78x	9.97x
Debt/Equity (TTM)	0.66x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.40	2.05
52W Performance	-9.9%	99.7%
YTD Performance	10.1%	54.5%
% from 52W High	-11.7%	-13.6%
% from 52W Low	109.3%	103.4%
Efficiency & Yields
Asset Turnover (TTM)	0.88x	0.07x
FCF Yield (TTM)	1.5%	-2.6%
Earnings Yield (TTM)	1.3%	-3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	37.0	-91.8
EV/GP/RG	0.86	N/A
Ticker research	View CAI research	View KYMR research

Valuation

P/E Ratio

CAI

79.91x

P/S Ratio

CAI

8.48x

KYMR

88.06x

EV/FCF

KYMR

-38.34x

CAI

65.33x

Growth & revenue

Revenue Growth TTM

KYMR

134.8%

CAI

24.4%

Forward Revenue Growth

CAI

18.2%

KYMR

-62.1%

Profitability & performance

Gross Margin

CAI

69.7%

KYMR

0.0%

ROE

CAI

18.8%

KYMR

-2150.0%

FCF Yield %

CAI

1.5%

KYMR

-2.6%

52-Week Performance

KYMR

99.7%

CAI

-9.9%

Detailed metrics comparison

CAI

Caris Life Sciences Inc

KYMR

Kymera Therapeutics Inc

Market Cap

CAI$8.40B

KYMR$9.25B

Enterprise Value

CAI$8.10B

KYMR$9.12B

Price

CAI$29.70

KYMR$112.40

P/E Ratio

CAI79.91x

KYMRN/A

P/S Ratio

CAI8.48x

KYMR88.06x

EV/Sales

CAI8.18x

KYMR86.90x

EV/EBITDA

CAI45.95x

KYMR0.00x

P/B Ratio

CAI13.52x

KYMR5.92x

P/FCF Ratio

CAI67.73x

KYMRN/A

EV/FCF

CAI65.33x

KYMR-38.34x

PEG Ratio

CAIN/A

KYMRN/A

Forward P/E (NTM)

CAI101.64x

KYMRN/A

Forward P/S (NTM)

CAI7.48x

KYMR456.91x

Revenue (TTM)

CAI$990M

KYMR$105M

Revenue Growth (YoY)

CAI24.4%

KYMR134.8%

Forward Rev Growth

CAI18.2%

KYMR-62.1%

Gross Margin (TTM)

CAI69.7%

KYMR0.0%

Operating Margin (TTM)

CAI12.7%

KYMR0.0%

EBITDA Margin (TTM)

CAI17.6%

KYMR-322.0%

Net Margin (TTM)

CAI10.6%

KYMR-285.3%

FCF Margin (TTM)

CAI12.5%

KYMR-226.6%

Net Income (TTM)

CAI$105M

KYMR$-300M

FCF (TTM)

CAI$124M

KYMR$-238M

EPS (TTM)

CAI$0.37

KYMR-$3.05

ROE (TTM)

CAI18.8%

KYMR-2150.0%

ROA (TTM)

CAI9.3%

KYMR-1946.0%

ROIC (TTM)

CAI11.2%

KYMR-2145.0%

Cash

CAI$691M

KYMR$124M

Debt

CAI$393M

KYMR$2M

Net Cash/Debt

CAI$298M

KYMR$122M

Current Ratio (TTM)

CAI5.53x

KYMR10.34x

Quick Ratio (TTM)

CAI4.78x

KYMR9.97x

Debt/Equity (TTM)

CAI0.66x

KYMR0.00x

Debt/Assets (TTM)

CAI0.0%

KYMR0.0%

Interest Coverage (TTM)

CAIN/A

KYMRN/A

Net Debt/EBITDA (TTM)

CAI0.00x

KYMR0.00x

Beta

CAI0.40

KYMR2.05

52W Performance

CAI-9.9%

KYMR99.7%

YTD Performance

CAI10.1%

KYMR54.5%

% from 52W High

CAI-11.7%

KYMR-13.6%

% from 52W Low

CAI109.3%

KYMR103.4%

Asset Turnover (TTM)

CAI0.88x

KYMR0.07x

FCF Yield (TTM)

CAI1.5%

KYMR-2.6%

Earnings Yield (TTM)

CAI1.3%

KYMR-3.2%

Dividend Yield (TTM)

CAIN/A

KYMRN/A

Rule of 40

CAI37.0

KYMR-91.8

EV/GP/RG

CAI0.86

KYMRN/A

Ticker research

View CAI research View KYMR research

Metric	CAI Caris Life Sciences Inc	KYMR Kymera Therapeutics Inc
Market & Valuation
Market Cap	$8.40B	$9.25B
Enterprise Value	$8.10B	$9.12B
Price	$29.70	$112.40
P/E Ratio	79.91x	N/A
P/S Ratio	8.48x	88.06x
EV/Sales	8.18x	86.90x
EV/EBITDA	45.95x	0.00x
P/B Ratio	13.52x	5.92x
P/FCF Ratio	67.73x	N/A
EV/FCF	65.33x	-38.34x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	101.64x	N/A
Forward P/S (NTM)	7.48x	456.91x
Revenue & Growth
Revenue (TTM)	$990M	$105M
Revenue Growth (YoY)	24.4%	134.8%
Forward Rev Growth	18.2%	-62.1%
Profitability
Gross Margin (TTM)	69.7%	0.0%
Operating Margin (TTM)	12.7%	0.0%
EBITDA Margin (TTM)	17.6%	-322.0%
Net Margin (TTM)	10.6%	-285.3%
FCF Margin (TTM)	12.5%	-226.6%
Net Income (TTM)	$105M	$-300M
FCF (TTM)	$124M	$-238M
EPS (TTM)	$0.37	-$3.05
ROE (TTM)	18.8%	-2150.0%
ROA (TTM)	9.3%	-1946.0%
ROIC (TTM)	11.2%	-2145.0%
Financial Health
Cash	$691M	$124M
Debt	$393M	$2M
Net Cash/Debt	$298M	$122M
Current Ratio (TTM)	5.53x	10.34x
Quick Ratio (TTM)	4.78x	9.97x
Debt/Equity (TTM)	0.66x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.40	2.05
52W Performance	-9.9%	99.7%
YTD Performance	10.1%	54.5%
% from 52W High	-11.7%	-13.6%
% from 52W Low	109.3%	103.4%
Efficiency & Yields
Asset Turnover (TTM)	0.88x	0.07x
FCF Yield (TTM)	1.5%	-2.6%
Earnings Yield (TTM)	1.3%	-3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	37.0	-91.8
EV/GP/RG	0.86	N/A
Ticker research	View CAI research	View KYMR research